Pre-chemotherapy treatment delays return of aggressive lymphoma


In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.

Engineered T cells help patients with relapsed B-ALL acheive remission

Engineered T cells help patients with relapsed B-ALL acheive remission

Treatment with autologous engineered T cells is effective bridge to potentially curative therapy

Ibrutinib may be a breakthrough for treatment of a rare lymphoma

Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.

Gene activity predicts course of chronic leukemia


A newly discovered molecular marker can distinguish aggressive chronic lymphocytic leukemia from a less aggressive form.

More chemotherapy might be best move for some children with leukemia

When induction therapy fails in acute lymphoblastic leukemia, some youths have better outcomes with more chemotherapy than with stem cell transplant.

Experimental agent acts against aggressive lymphoma subtype

The drug ibrutinib can provide significant anticancer responses with modest side effects in persons with diffuse large B-cell lymphomas (DLBCLs).

Survival improves for youths with leukemia

The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia rose from 83.7% for 1990-1994 to 90.4% for 2000-2005.

Intensive chemotherapy greatly improved survival for lymphoma patients

Survival improved significantly for persons younger than 60 years with diffuse large B-cell lymphoma when they underwent intensified chemotherapy compared with the standard regimen.

Entinostat shows which users are most likely to have delayed breast cancer progression

Clinical outcome can be predicted shortly after administration of the HDAC inhibitor entinostat among women with metastatic breast cancer, according to the company that developed the agent.

Diagnosis of non-Hodgkin's lymphoma

The non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of tumours of the lymphoid system and a relatively complex group of disorders. Presentation can be variable with many patients developing extranodal disease. The disease accounts for 4% of all cancer in the UK.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs